Member Info for OAPK20

Neil do you honestly think that the 7,371,557 shares issued on 19th December 2022 were not flipped in the rise to 4.8p area from 1.6p ? The concern maybe more to do with the MURF shareholders cashing in before the rto with Conduit. Hardly fills you with confidence does it.

The lack of confirmation of validation from CIZ and a lack of apparent reported progress is worrying.

Are they needing to draw down from the 500,000 option at 1.8p issue price already due to delays with MURF/Conduit ?

Maybe CIZ can provide reassurance to the market ? If they draw down the £500,000 in full that's further dilution by 27,777,778 shares approx. Maybe E3 Fund SP are forward selling.Who knows ? Initial drawdown of £50,000 (2,777,778 shares) could be drawn 180 days from 21st September 2022. So available from 20th March 2023.

It would be good to see the CEO update on progress with the CIZ1b test for lung cancer and if and when any drawdown happens. Looking at the SP some may already have an inkling.

In connection with such proposals, the Company’s public stockholders had the right to redeem their shares for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account as of two days prior to such stockholder vote. The Company’s public stockholders holding 11,037,272 shares of Class A common stock (out of a total of 13,979,000 shares of Class A common stock) exercised their right to redeem such shares at a redemption price of approximately $10.33 per share. Approximately $114 million in cash was removed from the Trust Account to pay such stockholders and, accordingly, after giving effect to such redemptions, the balance in the Trust Account was approximately $24 million.

As of May 11, 2023, there were 2,941,728 - Current MURF $10.55-$10.77

During the three months ended March 31, 2023, a total of 11,037,272, shares of Class A common stock were redeemed for $114,068,280 or approximately $10.33 per share.

This ?

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or until October 9, 2023 (the “Compliance Date”), to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Class A Common Stock must be at least $50 million for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company regains compliance with the MVLS Rule, Nasdaq will provide the Company with written confirmation and will close the matter.

MURF volume increasing. Wonder why?

Is there any details regarding milestone payments ?

95% accurate Elisa lab test.

£300,000,000 pa China licence alone

CorePath and more importantly CIZ need to get optimisation process completed and move to validation and commercialisation.

Greend - Using a minimally invasive blood draw, the Company's LungLB(R) test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Maybe some are spooked by LLAI update today. Trials staring. Already have US insurance approval for Medicare, Medicaid approval with a price of $2030 per test price point. Completed enrolment for LungLB study. Only 80% accurate though.

CIZ and CorePath need to get the finger out with the 95% accurate ELISA test.

DITTO. Once the update lands potential for a top slice and free ride.

Jan it was 1.4. One bag is nothing given the potential. If it is optimised, if it works, if it gets on US insurance approval lists, if it get Chinese approval, if it sells …….

Is it because he/WRE acquired the land/claims/licences proved them up to pre development, now selling them to LEX for a profit, retaining a 10% interest via LEX shares, so still benefits but does not have to spend anything on development/mining costs in future ?

Not a good look when it’s posted on a BB hours before a company RNS is it though

“ Ciz and Conduit are well informed re each other progress.”

Yep. Funny nothing this morning when the link was posted on this BB. CIZ got people reading these boards now ?

MURPH recommending voting for to their shareholders at their Shareholder Special meeting.

After careful consideration, the MURF Board has determined that the business combination proposal, the charter amendment proposals, the advisory charter amendments proposals, the director election proposal, the incentive plan proposal, the Nasdaq proposal and the adjournment proposal are fair to and in the best interests of MURF and its stockholders and unanimously recommends that you vote or give instruction to vote “FOR” the business combination proposal, “FOR” each of the charter amendment proposals, “FOR” each of the advisory charter amendments proposals, “FOR” the election of all of the persons nominated by MURF’s management for election as directors, “FOR” the incentive plan proposal, “FOR” the Nasdaq proposal and “FOR” the adjournment proposal, if presented.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1896212/000149315223016741/forms-4.htm

Bit of buying at MURPH.

Interesting. Been quiet there for a while. $7000 $3000 trades

Joe- That’s assuming they execute the Put at $10 and then immediately sell the shares at $10

What if they execute the Put at $10 and the Conduit price doubled on listing.

CIZ would hold approx 406,250 Shares in Conduit at $20 or £6,500,000 . Sell then maybe or ride it out.

Must pump harder

Joe - What’s your thoughts ? 14/4/2023.

On April 10, 2023, Murphy Canyon Acquisition Corp. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, for the previous 30 consecutive business days, the Market Value of Listed Securities (“MVLS”) for the Class A Common Stock of the Company, par value $0.0001 per share (“Class A Common Stock”), was below the $50 million minimum MVLS requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”). The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities.

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or until October 9, 2023 (the “Compliance Date”), to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Class A Common Stock must be at least $50 million for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company regains compliance with the MVLS Rule, Nasdaq will provide the Company with written confirmation and will close the matter.

If the Company does not regain compliance with the MVLS Rule by the Compliance Date, Nasdaq will provide notice that the Class A Common Stock will be subject to delisting. In the event of such notification, the Nasdaq rules permit the Company an opportunity to appeal Nasdaq’s determination.

Whose in?